226. Interstitial cystitis with Hunners ulcer Clinical trials / Disease details
Clinical trials : 145 / Drugs : 156 - (DrugBank : 51) / Drug target genes : 64 - Drug target pathways : 146
Showing 1 to 8 of 8 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2009-014597-17-SE (EUCTR) | 03/05/2010 | 28/10/2009 | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY ... | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY ... | Chronic pain including the pain of interstitial cystitis/painful bladder syndrome. MedDRA version: 12.0;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis Chronic pain including the pain of interstitial cystitis/painful bladder syndrome. MedDRA version: 1 ... | Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name ... | Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2 | Finland;Spain;Belgium;Germany;Sweden | ||
| 2 | EUCTR2009-014597-17-FI (EUCTR) | 24/03/2010 | 04/12/2009 | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY ... | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY ... | Chronic pain including the pain of interstitial cystitis/painful bladder syndrome. MedDRA version: 12.0;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis Chronic pain including the pain of interstitial cystitis/painful bladder syndrome. MedDRA version: 1 ... | Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name ... | Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2 | Slovakia;Finland;Spain;Belgium;Germany;Sweden | ||
| 3 | EUCTR2009-014597-17-DE (EUCTR) | 19/03/2010 | 03/12/2009 | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY ... | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY ... | Chronic pain including the pain of interstitial cystitis/painful bladder syndrome. MedDRA version: 12.0;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis Chronic pain including the pain of interstitial cystitis/painful bladder syndrome. MedDRA version: 1 ... | Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name ... | Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2 | Finland;Germany;Belgium;Spain;Sweden | ||
| 4 | EUCTR2009-014597-17-ES (EUCTR) | 08/02/2010 | 12/11/2009 | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS)ESTUDIO EN FASE 2B, ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON PLACEBO DE DETERMINACIÓN DE DOSIS PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE TANEZUMAB EN EL TRATAMIENTO DEL DOLOR MODERADO A INTENSO ASOCIADO A CISTITIS INTERSTICIAL/SÍNDROME DE LA VEJIGA DOLOROSA (CI/SVD) A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY ... | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS)ESTUDIO EN FASE 2B, ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON PLACEBO DE DETERMINACIÓN DE DOSIS PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE TANEZUMAB EN EL TRATAMIENTO DEL DOLOR MODERADO A INTENSO ASOCIADO A CISTITIS INTERSTICIAL/SÍNDROME DE LA VEJIGA DOLOROSA (CI/SVD) A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY ... | Tratamiento del dolor crónico incluyendo el dolor debido a cististis intersticial/síndrome de la vejiga dolorosa MedDRA version: 12.0;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis Tratamiento del dolor crónico incluyendo el dolor debido a cististis intersticial/síndrome de la vej ... | Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name ... | Pfizer, S.A. | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2 | Finland;Belgium;Spain;Germany;Sweden | ||
| 5 | EUCTR2009-014597-17-SK (EUCTR) | 03/02/2010 | 11/02/2010 | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY ... | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY ... | Chronic pain including the pain of interstitial cystitis/painful bladder syndrome. MedDRA version: 12.0;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis Chronic pain including the pain of interstitial cystitis/painful bladder syndrome. MedDRA version: 1 ... | Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name ... | Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2 | Slovakia;Finland;Spain;Belgium;Germany;Sweden | ||
| 6 | NCT00999518 (ClinicalTrials.gov) | January 22, 2010 | 20/10/2009 | A Study To Investigate Tanezumab In Patients With Interstitial Cystitis/ Painful Bladder Syndrome | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS). A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY ... | Cystitis, Interstitial | Biological: Tanezumab;Other: Placebo | Pfizer | NULL | Terminated | 18 Years | N/A | All | 205 | Phase 2 | United States;Belgium;Canada;Finland;Hong Kong;Japan;Korea, Republic of;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Germany;India;South Africa United States;Belgium;Canada;Finland;Hong Kong;Japan;Korea, Republic of;Poland;Romania;Russian Feder ... |
| 7 | EUCTR2009-014597-17-BE (EUCTR) | 24/12/2009 | 09/11/2009 | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY ... | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY ... | Chronic pain including the pain of interstitial cystitis/painful bladder syndrome. MedDRA version: 12.0;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis Chronic pain including the pain of interstitial cystitis/painful bladder syndrome. MedDRA version: 1 ... | Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name ... | Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2 | Slovakia;Finland;Spain;Belgium;Germany;Sweden | ||
| 8 | NCT01030640 (ClinicalTrials.gov) | December 2009 | 9/12/2009 | Study To Assess Changes In The Number Of Nerves In The Skin At The Site Where Where Tanezumab Is Injected Study To Assess Changes In The Number Of Nerves In The Skin At The Site Where Where TanezumabIs Inje ... | A Phase 1, Randomized, Double- Blind (Sponsor-Open), Placebo-Controlled Study To Examine The Density Of Intraepidermal Nerve Fibers After A Single Subcutaneous Administration Of Tanezumab In Healthy Volunteers A Phase 1, Randomized, Double- Blind (Sponsor-Open), Placebo-Controlled Study To Examine The Density ... | Osteoarthritis Pain;Chronic Low Back Pain;Pain Due to Interstitial Cystitis | Other: placebo;Biological: tanezumab | Pfizer | NULL | Completed | 18 Years | 55 Years | Both | 28 | Phase 1 | United States |